Hepatitis B Virus

Hepatitis B virus, abbreviated HBV, is a double stranded DNA virus, a species of the genus Orthohepadnavirus, and a member of the Hepadnaviridae family of viruses. This virus causes the disease hepatitis B.

Vesicular Stomatitis Virus

is a virus in the family Rhabdoviridae; the well-known rabies virus belongs to the same family. VSV can infect insects, cattle, horses, and pigs.

Semliki Forest Virus

The Semliki Forest virus is a positive-stranded RNA virus with a genome of approximately 13,000 nucleotides, which encodes nine proteins. It is known to cause disease in animals including humans.

We are an immunotherapy company!

Our vision is to create a wave of transformative, first-in-class immunotherapeutics designed to engage the body's immune system to both recognize and fight off infectious diseases and cancer. We are leveraging our VLV platform to develop a portfolio of products against diseases of high unmet need...

Our Press Release

June 18, 2018, Farmington, CT - CaroGen, a developer of transformative immunotherapies for infectious disease and cancer, having its initial focus on development of a cure for patients with chronic hepatitis B (CHB), announced that the Company has selected a candidate for advancement into clinical studies. The candidate Virus-Like Vesicle (VLV), known as CARG-101, has many attributes that make it attractive for advancement including expression of three major antigens from Hepatitis B Virus (HBV).

Harry H. Penner, the former CEO of Neurogen and a serial entrepreneur, joins the Board of Directors of CaroGen

June 12, 2018, Farmington, CT - CaroGen, a developer of transformative immunotherapies for infectious disease and cancer, having its initial focus on development of a cure for patients chronically infected with hepatitis B virus (HBV), today announced that the company has appointed Mr. Harry Penner to serve on the company's board of directors.

CaroGen Strengthens its Board and Discovery Team

April 17, 2017, Farmington, CT - CaroGen Corp, a developer of immunotherapies for HBV as well as other infectious diseases and cancer, announced today an important addition to its Board of Directors and two key senior executive level scientists to its immunotherapy discovery and development team. Bijan Almassian, Ph.D., CaroGen’s CEO stated that, “The addition of these three impressive and experienced individuals, greatly strengthens the CaroGen team and positions the company well with respect to executing on its immunotherapy plans”.

November 8, 2016, Farmington, CT -- The University of Connecticut and CaroGen Corporation, an emerging immunotherapy company, today announced a collaboration aimed at developing a therapeutic vaccine for treatment of patients with colon cancer. CaroGen’s proprietary technology platform will be applied to a specific target studied by UConn Health’s Dr. Kepeng Wang Ph.D., Assistant Professor of Immunology. CaroGen will support this effort with a $70,000 grant to Dr. Wang, and his collaborator Dr. Anthony T. Vella, Ph.D., Professor and Boehringer Ingelheim Chair in Immunology, who will aid in the development of this platform.